Physician

Ernesto Bustinza Linares, M.D.

According to 2025 Medicare claims, Ernesto Linares, M.D. (NPI: 1598966509) practices hematology/oncology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32763-8399. Linares is affiliated with the Complete Health Accountable Care LLC (ACO ID: D0036), participating under the REACH model.

Linares' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 638 traditional Medicare patients, billed 223,622 HCPCS/CPT codes, and received $2,925,246 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,308 prescription claims across 292 beneficiaries totaling $4,122,654 in drug costs, led by Revlimid (Lenalidomide). DME data shows 34 claims. Open Payments data shows 135 records totaling $2,879. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $200,054 to $2,925,246. Similarly, Part D prescription costs have risen steadily, from $37,330 to $4,122,654. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	391	13,745	$200,054
2016	501	79,473	$726,798
2017	668	90,047	$1,002,277
2018	678	135,547	$1,614,868
2019	794	201,913	$2,117,938
2020	704	268,736	$3,035,409
2021	682	261,236	$3,678,908
2022	577	181,480	$2,700,506
2023	674	237,508	$3,435,138
2024	638	223,622	$2,925,246

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	123	367	$37,330
2016	88	411	$303,436
2017	121	559	$302,929
2018	163	935	$1,215,139
2019	188	1,003	$1,743,192
2020	245	1,590	$2,625,731
2021	327	2,009	$2,767,348
2022	302	1,688	$3,095,763
2023	339	1,429	$3,082,392
2024	292	1,308	$4,122,654

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	34	$1,086

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	152	394	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	317	650	$64
96372	Injection of drug or substance under skin or into muscle	182	649	$10
36415	Insertion of needle into vein for collection of blood sample	475	1,641	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	465	1,755	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	53	1,463	$691,519
Jakafi	Ruxolitinib Phosphate	25	750	$451,682
Ojjaara	Momelotinib Dihydrochloride	13	390	$365,850
Imbruvica	Ibrutinib	16	448	$262,469
Tavalisse	Fostamatinib Disodium	12	360	$178,945

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$690
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$284
J8520	Capecitabine, oral, 150 mg	N	N/R	11	$112

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	135	$2,879	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ernesto Bustinza Linares, M.D.?

Tedicare shows public-source Medicare data for Ernesto Bustinza Linares, M.D. (NPI 1598966509), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ernesto Bustinza Linares, M.D. have ACO affiliation data?

Ernesto Bustinza Linares, M.D. is shown with ACO affiliation data for Complete Health Accountable Care LLC (REACH, ACO ID D0036).

What billing organization is linked to Ernesto Bustinza Linares, M.D.?

Ernesto Bustinza Linares, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Ernesto Bustinza Linares, M.D. have Open Payments data?

Ernesto Bustinza Linares, M.D. has 135 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.